x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

0,964
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Science Citation Index Expanded, Journal of Citation Reports, Index Medicus/MEDLINE, Scopus, EMBASE/Excerpta Medica, IBECS

Métricas

  • Factor de Impacto: 0,964(2015)
  • 5-años Factor de Impacto: 0,947
  • SCImago Journal Rank (SJR):0,34
  • Source Normalized Impact per Paper (SNIP):0,612
doi: 10.1016/S0210-4806(07)73701-4
Estado actual del ultrasonido de alta frecuencia (HIFU) en el tratamiento del adenocarcinoma prostático
Current state of high intensity focused ultrasound (hifu) as treatment of prostatic carcinoma
E. Lledó García1, , J. Jara Rascón, F. Herranz Amo, C. Hernández Fernández
Servicio de Urología. Hospital General Universitario Gregorio Marañón. Madrid
Resumen
Objetivo

Evaluar el estado actual de la utilización del Ultrasonido de Alta Intensidad (HIFU) en el tratamiento del adenocarcinoma prostático (Cap).

Método

Hemos llevado a cabo una revisión del papel actual del HIFU en el tratamiento del Cap.

Resultados

La tecnología HIFU está actualmente siendo aplicada ya de forma habitual en Europa en el tratamiento del Cap. Las indicaciones principales en la actualidad son dos: la aplicación del HIFU como primer escalón terapéutico y como terapia de rescate en recidivas post-radioterapia. Los trabajos actuales están basados en equipos clínicos en desarrollo. Aunque las últimas publicaciones sugieren que HIFU es una forma de tratamiento útil para el Cap bien y moderadamente diferenciado, existe todavía falta de comparaciones de esta terapia menos invasiva con los tratamientos estándar. Seguimos detectando en los trabajos disparidad en la definición de supervivencia libre de enfermedad (SLE), lo que dificulta la interpretación de resultados y la extracción de conclusiones definitivas.

Conclusiones

La experiencia de los grupos de trabajo especializados en HIFU es altamente prometedora. Entre los aspectos a destacar está su gran capacidad de destrucción tumoral local tanto en los casos primarios como en las recidivas post-radioterapia. Para extraer conclusiones a medio y largo plazo debemos generar ensayos clínicos randomizados y controlados con seguimiento suficiente para medir beneficios en términos de supervivencia global y calidad de vida (balance efectos adversos / beneficios), realizar comparaciones con las terapias estándar y homogeneizar los criterios de definición de la SLE.

Abstract
Objective

To evaluate the current state of high intensity focused ultrasound as therapeutical option of prostatic carcinoma (PCa)

Methods

We completed an extense review of urologic literature on the role of HIFU on the treatment of PCa.

Results

This technique is nowadays usually being indicated in Europe as treatment of many cases of either primary or relapsed PCa after radiotherapy. Although some reports suggest that HIFU is very effective as treatment for low and medium risk localized PCa patients, no randomized series comparing this technique with conventional therapies have been presented yet. Great disparity in criteria to define free-disease survival is detected, which make difficult the interpretation of results.

Conclusions

Experience of some groups in HIFU is highly promising. Local tumour destruction is evident both in primary and relapsed PCa cases. To make conclusions in the long-term, controlled-randomized trials must be designed, with follow-up to measure benefits in global survival and quality of live. Comparisons must be completed with conventional techniques, and a uniform definition of disease free-survival is necessary.

Palabras clave
Ultrasonido de alta frecuencia (HIFU), Adenocarcinoma prostático
Key words
High intensity focused ultrasound (HIFU), Prostatic carcinoma
El Texto completo solo esta disponible en PDF
Referencias
1.
A. Blana,B. Walter,S. Rogenhofer,W.F. Wieland
High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience
Urology, 63 (2004), pp. 297-300
2.
S. Hummel,S. Paisley,A. Morgan,E. Curie,N. Brewer
Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review
Health Technol Assess, 7 (2003), pp. 1-157
3.
F. Herranz Amo,F. Arias Funez,M. Arrizabalaga Moreno,F.J. Calahorra Fernández,J. Carballido Rodríguez,R. Diz Rodríguez
El cáncer de próstata en la Comunidad de Madrid en el año 2000. I-Incidencia
Actas Urol. Esp, 27 (2003), pp. 323-334
4.
P. Huber,J. Debus,J. Jenne,K. Jöchle,G. van Kaick,W.J. Lorenz
Therapeutic ultrasound in tumor therapy: principles, applications and new developments
Radiologe, 36 (1996), pp. 64-71
5.
J.Y. Chapelon,J. Margonari,F. Vernier,F. Gorry,R. Ecochard,A. Gelet
In-vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327
Cancer Res, 52 (1996), pp. 6353-6357
6.
C.G. Chaussy,S. Thüroff
High-Intensity focused ultrasound in localized prostate cancer
J Endourol, 14 (2000), pp. 293-299
7.
C. Chaussy,S. Thürof,X. Rebillard,A. Gelet
Technology insight: high-intensity focused ultrasound for urologic cancers
Nat Clin Pract Urol, 2 (2005), pp. 191-198
8.
G. Ter Haar
Intervention and therapy
Ultrasound Med Biol, 26 (2000), pp. 51-54
9.
J.Y. Chapelon,J. Margonari,Y. Theillère,F. Gorry,F. Vernier,E. Blanc
Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog
Eur Urol, 22 (1992), pp. 147-152
10.
Kishi M. Expermiental studies of effects of intense ultrasound on implantable murine glioma. In: Proceedings of the 2nd European Congress on Ultrasonics in Medicine: 28-33 (Eds Kazmer E et al). Amsterdam, Excerpta Medica 1975
11.
W.E. Moore,R.M. Lopez,D.E. Matthews,P.W. Sheets,M.R. Etchison,A.S. Hurwitz
Evaluation of high-intensity therapeutic ultrasound irradiation in the treatment of experimental hepatoma
J Pediatr Surg, 24 (1989), pp. 30-33
12.
R. Yang
High-intensity focused ultrasound on prostatic adenocarcinoma Dunning R3327
Cancer Res, 52 (1991), pp. 6353-6357
13.
G.O. Oosterhof,E.B. Cornel,G.A. Smits,F.M. Debruyne,J.A. Schalken
In vivo effects of high-intensity focused ultrasound on the development of metastases
Eur Urol, 32 (1997), pp. 91-95
14.
C. Damianou
In vitro and in vivo ablation of porcine renal tissues using high-intensity focused ultrasound
Ultrasound Med Biol, 29 (2003), pp. 1321-1330
15.
A. Gelet,J.Y. Chapelon,J. Margonari,Y. Theillere,F. Gorry,D. Cathignol
Prostatic tissue destruction by highintensity focused ultrasound: experimentation on canine prostate
J Endourol, 7 (1993), pp. 249-253
16.
G. Vallancien,E. Chartier-Kastler,M. Harouni,D. Chopin,J. Bougaran
Focused extracorporeal pyrotherapy: experimental study and feasibility in man
Semin Urol, 11 (1993), pp. 7-9
17.
F. Wu,Z.B. Wang,W.Z. Chen,J. Bai,H. Zhu,T.Y. Qiao
Preliminary experience using high-intensity focused ultrasound for the treatment of patients with advanced stage renal malignancy
J Urol, 170 (2003), pp. 2237-2240
18.
F.A. Critz
A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition
J Urol, 167 (2002), pp. 1310-1313
19.
S. Thüroff,C. Chaussy,G. Vallancien,W. Wieland,H.J. Kil,A. Le Duc
High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study
J Endourol, 17 (2003), pp. 673-677
20.
A. Gelet,J.Y. Chapelon,L. Poisonier,R. Bouvier,O. Rouvière,L. Curiel
Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography
Urology, 63 (2004), pp. 625-629
21.
J.W. Moul
Variables in predicting survival based on treating “PSA-only” relapse
Urol Oncol, 21 (2003), pp. 292-304
22.
C.L. Amling,E.J. Bergstralh,M.L. Blute,J.M. Slezak,H. Zincke
Defining prostate specific antigen pogresion after radical prostatectomy: what is the most appropiate cut point?
J Urol, 165 (2001), pp. 1146-1151
23.
Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel
Int J Radiat Oncol Biol Phys, 1537 (1997), pp. 1035-1041
24.
E.M. Horwitz,R.G. Uzzo,A.L. Hanlon,R.E. Greenberg,G.E. Hanks,A. Pollack
Modifying the American Society fo therapeutic radiology and oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
J Urol, 169 (2003), pp. 2153-2157
25.
A. Gelet,J.Y. Chapelon,R. Bouvier,O. Rouviere,L. Poissonier,G. Pasticier
Transrectal focused ultrasound and localized prostate cancer: may the nadir PSA predict the treatment success?
European Urology Supplements, 3 (2004), pp. 213
26.
S. Thüroff,H.J. Kiel,C. Chausy
Local histopathological efficacy of HIFU
European Urology Supplements, 3 (2004), pp. 213
27.
C. Chaussy,S. Thüroff,H.J. Kiel
Transrectal High Intensity Focused Ultrasound for Prostate Cancer: impact of the energy dose
European Urology Supplements, 3 (2004), pp. 213
28.
R.A. Stephenson
Population-based prostate cancer trends in the PSA-era: data from the surveillance, epidemiology and end results program
Mongr Urol, 19 (1998), pp. 1-19
29.
A.V. D’Amico,K. Cote,M. Loffredo,A.A. Renshaw,M.H. Chen
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure
J Urol, 169 (2003), pp. 1320-1324
30.
C.L. Amling,S.E. Lerner,S.K. Martin,J.M. Slezak,M.L. Blute,H. Zincke
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer
J Urol, 161 (1999), pp. 857-862
31.
G.L. Grado,J.M. Collins,J.S. Kriegshauser
Salvage brachytherapy for localized prostate cancer after radiotherapy failure
Urology, 53 (1999), pp. 2-10
32.
L.L. Pisters,A.C. von Eschenbach,S.M. Scott,D.A. Swanson,C.P. Dinney,C.A. Pettaway
The efficacy and complications of salvage criotherapy of the prostate
J Urol, 157 (1997), pp. 921-925
33.
X. Rebillard,J.L. Davin,M. Soulie
Comité de Cancerologie de l´Associacion Francaise d´Urologie
Progr Urol, 13 (2003), pp. 1428-1456
Correspondencia autor: Dr. E. Lledó García Servicio de Urología. Hospital General Univ. Gregorio Marañón Doctor Esquerdo, 46 - 28007 Madrid. Tel.: 915 868 000
Copyright © 2007. Asociación Española de Urología (AEU)